Compare EDRY & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDRY | PMN |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | Greece | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.8M | 84.1M |
| IPO Year | 2018 | 2022 |
| Metric | EDRY | PMN |
|---|---|---|
| Price | $60.79 | $9.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $45.33 | $42.71 |
| AVG Volume (30 Days) | ★ 182.9K | 31.5K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $40.95 | N/A |
| Revenue Next Year | $8.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.95 | $0.29 |
| 52 Week High | $73.07 | $27.40 |
| Indicator | EDRY | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 29.40 |
| Support Level | $17.86 | $9.20 |
| Resistance Level | $73.07 | $15.37 |
| Average True Range (ATR) | 6.40 | 0.92 |
| MACD | -0.46 | -0.25 |
| Stochastic Oscillator | 50.24 | 9.92 |
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.